Transaction Agreement Details: Mural Oncology (MURA) has finalized the Additional Price Per Share as $0.000, leading to a total cash consideration of $2.035 per share for Mural shareholders upon closing of the Acquisition.
Acquisition Overview: The Acquisition involves XOMA Royalty Corporation acquiring the entire issued share capital of Mural through a scheme sanctioned by the Irish High Court, expected to close in early December 2025.
Parties Involved: The transaction is between Mural Oncology, XOMA Royalty Corporation, and XRA 5 Corp., with XOMA's subsidiary set to execute the acquisition.
Regulatory Approval: The completion of the Acquisition is contingent upon meeting outstanding closing conditions and receiving approval from the Irish High Court.
Wall Street analysts forecast XOMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XOMA is 69.67 USD with a low forecast of 50.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast XOMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XOMA is 69.67 USD with a low forecast of 50.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 28.790
Low
50.00
Averages
69.67
High
104.00
Current: 28.790
Low
50.00
Averages
69.67
High
104.00
Lucid Capital
NULL -> Buy
initiated
$76
Al Analysis
2025-12-09
Reason
Lucid Capital
Price Target
$76
Al Analysis
2025-12-09
initiated
NULL -> Buy
Reason
Lucid Capital initiated coverage of Xoma with a Buy rating and $76 price target. The company has assembled a royalty portfolio from six commercial and nine Phase 3- stage small molecule and biological assets, the analyst tells investors in a research note. The firm says Xoma expects to collect over $1B in milestones and royalties over the next 15 years. Lucid believes that by building a diversified portfolio, the company mitigates single-asset risk while retaining exposure to substantial long-term value creation.
Benchmark
Robert Wasserman
Strong Buy
Initiates
$35
2025-04-17
Reason
Benchmark
Robert Wasserman
Price Target
$35
2025-04-17
Initiates
Strong Buy
Reason
Benchmark analyst Robert Wasserman initiated coverage of Xoma with a Buy rating and $35 price target. Xoma has expanded its royalty aggregate business through acquisitions and internal growth over the past several years, notes the analyst, who expects the R&D pipeline and recently completed commercial asset acquisitions to continue to drive double digit revenue growth over the next several years.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for XOMA
Unlock Now
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$104
2025-03-28
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$104
2025-03-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$104
2025-03-19
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$104
2025-03-19
Reiterates
Strong Buy
Reason
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
